Abstract
Equine gastric ulcer disease is a widespread condition affecting up to 90% of sport horses, characterised by erosive lesions of the gastric mucosa and chronic inflammation. Standard therapy with proton pump inhibitors (omeprazole) reduces gastric acidity but does not address the underlying immune dysregulation driving disease chronicity. An imbalance of cytokines — elevated pro-inflammatory mediators (tumour necrosis factor alpha — TNFα, interleukin-1β — IL-1β, interleukin-6 — IL-6) alongside reduced anti-inflammatory signals (interleukin-4 — IL-4, interleukin-10 — IL-10) — is considered a key pathogenic mechanism. The aim of this study was to evaluate the efficacy of targeted anti-cytokine therapy with antiTNFα monoclonal antibodies as an adjunct to standard gastric ulcer disease treatment. Thirty horses with endoscopically confirmed gastric ulcer disease were divided into a control group (omeprazole 4 mg/kg/24 h, n=15) and a study group (omeprazole 4 mg/kg/24 h plus a single intravenous infusion of anti-TNFα monoclonal antibodies 5 mg/kg, n=15). Serum cytokine levels (TNFα, IL-1β, IL-6, IL-4, IL-10) were measured by enzyme-linked immunosorbent assay (ELISA) at baseline, 6 h, 24 h, and 8 days. In the study group, rapid and pronounced suppression of pro-inflammatory cytokines was recorded: TNFα decreased by 96% at 24 h, IL-1β by 82%, and IL-6 by 80% (p < 0.001). Simultaneously, anti-inflammatory responses increased: IL-4 and IL-10 rose by 75% and 68%, respectively, by day 8. The TNFα/IL-10 ratio declined 50-fold, indicating restoration of immune homeostasis. No significant cytokine dynamics were observed in the control group. Targeted anticytokine therapy with anti-TNFα monoclonal antibodies represents a promising immunomodulatory approach to gastric ulcer disease treatment, addressing an existing therapeutic gap.

This publication has 15 references indexed in Scilit: